Ocular Surface Disease

With this expansion, BostonSight reinforces its commitment to advancing care for patients with severe ocular surface disease and irregular corneas.

The study's primary objective was to demonstrate that LUMIFY Preservative Free redness reliever eye drops are noninferior to LUMIFY redness reliever eye drops in reducing ocular redness.

Study authors Preeya K. Gupta, MD; and Paul Karpecki, OD, formulated a case in their literature review for the routine evaluation of the upper eyelid during meibomian gland imaging.

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

The report categorizes research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

The generic formulation references Pred Forte, which is trademarked by Allergan.

The OTC eye drops contain low-dose brimonidine tartrate 0.025%.

BRS Analytical Service, LLC, an independent contract testing laboratory, initiated the recall because of possible concerns about product quality and safety linked to the manufacturing process. An FDA audit revealed serious manufacturing violations of Current Good Manufacturing Practice.

Identifying allergens or irritants can be challenging, but a few strategies can help patients find relief.

Inflammation is both a cause and consequence of dry eye disease.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

An overview of prescription medications available for DED.

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

Preservatives may disrupt the ocular surface, contributing to poor adherence.

From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.

This year was brimming with advancements in eye care.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

A few optometrists share which innovations in optometry they were most excited about in 2024.

Inside the role of blepharitis in ocular surface disease and effective management strategies.